Signature Gene Expression Profiles Discriminate between Isoniazid-, Thiolactomycin-, and Triclosan-Treated Mycobacterium tuberculosis

ABSTRACT Genomic technologies have the potential to greatly increase the efficiency of the drug development process. As part of our tuberculosis drug discovery program, we used DNA microarray technology to profile drug-induced effects in Mycobacterium tuberculosis. Expression profiles of M. tuberculosis treated with compounds that inhibit key metabolic pathways are required as references for the assessment of novel antimycobacterial agents. We have studied the response of M. tuberculosis to treatment with the mycolic acid biosynthesis inhibitors isoniazid, thiolactomycin, and triclosan. Thiolactomycin targets the β-ketoacyl-acyl carrier protein (ACP) synthases KasA and KasB, while triclosan inhibits the enoyl-ACP reductase InhA. However, controversy surrounds the precise mode of action of isoniazid, with both InhA and KasA having been proposed as the primary target. We have shown that although the global response profiles of isoniazid and thiolactomycin are more closely related to each other than to that of triclosan, there are differences that distinguish the mode of action of these two drugs. In addition, we have identified two groups of genes, possibly forming efflux and detoxification systems, through which M. tuberculosis may limit the effects of triclosan. We have developed a mathematical model, based on the expression of 21 genes, which is able to perfectly discriminate between isoniazid-, thiolactomycin-, or triclosan-treated M. tuberculosis. This model is likely to prove invaluable as a tool to improve the efficiency of our drug development programs by providing a means to rapidly confirm the mode of action of thiolactomycin analogues or novel InhA inhibitors as well as helping to translate enzyme activity into whole-cell activity.

[1]  C. Mateo,et al.  Membranotropic effects of the antibacterial agent Triclosan. , 2001, Archives of biochemistry and biophysics.

[2]  J. Content,et al.  The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. , 2000, FEMS microbiology reviews.

[3]  C. Volker,et al.  Purification and Biochemical Characterization of theMycobacterium tuberculosis β-Ketoacyl-acyl Carrier Protein Synthases KasA and KasB* , 2001, The Journal of Biological Chemistry.

[4]  G. Besra,et al.  Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis , 1996, Antimicrobial agents and chemotherapy.

[5]  Ricardo Macarron,et al.  Novel antibacterials: a genomics approach to drug discovery. , 2002, Current drug targets. Infectious disorders.

[6]  T. Weisbrod,et al.  Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in Mycobacterium tuberculosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Schoolnik,et al.  DNA microarrays and combinatorial chemical libraries: tools for the drug discovery pipeline. , 2000, The International Journal of Tuberculosis and Lung Disease.

[8]  S. Parikh,et al.  Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. , 2000, Biochemistry.

[9]  A. Kawaguchi,et al.  Inhibition of fatty acid synthesis by the antibiotic thiolactomycin. , 1984, The Journal of antibiotics.

[10]  T. Schaeverbeke,et al.  In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas. , 1999, The Journal of antimicrobial chemotherapy.

[11]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[12]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[13]  Preston Hunter,et al.  Genome-directed primers for selective labeling of bacterial transcripts for DNA microarray analysis , 2000, Nature Biotechnology.

[14]  N. Cairns,et al.  The quantification of gene expression in an animal model of brain ischaemia using TaqMan real-time RT-PCR. , 2002, Brain research. Molecular brain research.

[15]  J. D. Douglas,et al.  Analogues of thiolactomycin: potential drugs with enhanced anti-mycobacterial activity. , 2002, Microbiology.

[16]  R. O'brien,et al.  The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. , 2001, American journal of respiratory and critical care medicine.

[17]  J. Fostel,et al.  Genome-Wide Expression Patterns inSaccharomyces cerevisiae: Comparison of Drug Treatments and Genetic Alterations Affecting Biosynthesis of Ergosterol , 2000, Antimicrobial Agents and Chemotherapy.

[18]  W Keck,et al.  Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. , 2001, Genome research.

[19]  P. Brown,et al.  Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. McDermott,et al.  Genetic Evidence that InhA of Mycobacterium smegmatis Is a Target for Triclosan , 1999, Antimicrobial Agents and Chemotherapy.

[21]  R. Slayden,et al.  Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis , 2000, Molecular microbiology.

[22]  Wai-Leung Ng,et al.  Transcriptional Regulation and Signature Patterns Revealed by Microarray Analyses of Streptococcus pneumoniae R6 Challenged with Sublethal Concentrations of Translation Inhibitors , 2003, Journal of bacteriology.

[23]  J. Betts,et al.  Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.

[24]  D. Ruppert.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction , 2004 .

[25]  J. Betts.  Transcriptomics and Proteomics: Tools for the Identification of Novel Drug Targets and Vaccine Candidates for Tuberculosis , 2002, IUBMB life.

[26]  R. Heath,et al.  Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics , 2002, Applied Microbiology and Biotechnology.

[27]  H. Nikaido,et al.  The envelope of mycobacteria. , 1995, Annual review of biochemistry.

[28]  James C. Sacchettini,et al.  Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis , 2000, Journal of bacteriology.

[29]  D Alland,et al.  Thiolactomycin and Related Analogues as Novel Anti-mycobacterial Agents Targeting KasA and KasB Condensing Enzymes inMycobacterium tuberculosis * , 2000, The Journal of Biological Chemistry.

[30]  G. Besra,et al.  Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis , 2002, Molecular microbiology.

[31]  J C Sacchettini,et al.  Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.

[32]  David A. Mead,et al.  Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP synthase by isoniazid , 1998 .